AU2005288737B2 - Combination comprising ZD6474 and imatinib - Google Patents

Combination comprising ZD6474 and imatinib Download PDF

Info

Publication number
AU2005288737B2
AU2005288737B2 AU2005288737A AU2005288737A AU2005288737B2 AU 2005288737 B2 AU2005288737 B2 AU 2005288737B2 AU 2005288737 A AU2005288737 A AU 2005288737A AU 2005288737 A AU2005288737 A AU 2005288737A AU 2005288737 B2 AU2005288737 B2 AU 2005288737B2
Authority
AU
Australia
Prior art keywords
imatinib
effective amount
pharmaceutically acceptable
warm
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005288737A
Other languages
English (en)
Other versions
AU2005288737A1 (en
Inventor
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421438A external-priority patent/GB0421438D0/en
Priority claimed from GB0506726A external-priority patent/GB0506726D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2005288737A1 publication Critical patent/AU2005288737A1/en
Application granted granted Critical
Publication of AU2005288737B2 publication Critical patent/AU2005288737B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005288737A 2004-09-27 2005-09-23 Combination comprising ZD6474 and imatinib Ceased AU2005288737B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0506726.9 2004-04-01
GB0421438.3 2004-09-27
GB0421438A GB0421438D0 (en) 2004-09-27 2004-09-27 Combination therapy
GB0506726A GB0506726D0 (en) 2005-04-01 2005-04-01 Combination therapy
PCT/GB2005/003673 WO2006035204A2 (en) 2004-09-27 2005-09-23 Combination comprising zd6474 and an imatinib

Publications (2)

Publication Number Publication Date
AU2005288737A1 AU2005288737A1 (en) 2006-04-06
AU2005288737B2 true AU2005288737B2 (en) 2008-08-14

Family

ID=35924044

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005288737A Ceased AU2005288737B2 (en) 2004-09-27 2005-09-23 Combination comprising ZD6474 and imatinib

Country Status (11)

Country Link
US (2) US20080119479A1 (enExample)
EP (1) EP1804802A2 (enExample)
JP (1) JP2008514577A (enExample)
KR (1) KR20070072543A (enExample)
AU (1) AU2005288737B2 (enExample)
BR (1) BRPI0516052A (enExample)
CA (1) CA2578956A1 (enExample)
IL (1) IL181609A0 (enExample)
MX (1) MX2007003505A (enExample)
NO (1) NO20071428L (enExample)
WO (1) WO2006035204A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
EP3352107B1 (en) 2008-03-03 2025-10-22 NIKE Innovate C.V. Interactive athletic equipment system
US8628453B2 (en) 2008-12-05 2014-01-14 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
US20100184564A1 (en) 2008-12-05 2010-07-22 Nike, Inc. Athletic Performance Monitoring Systems and Methods in a Team Sports Environment
US8231506B2 (en) 2008-12-05 2012-07-31 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
CA2955632A1 (en) 2010-11-10 2012-05-18 Nike Innovate C.V. Systems and methods for time-based athletic activity measurement and display
EP2676212B1 (en) 2011-02-17 2022-03-16 NIKE Innovate C.V. Selecting and correlating physical activity data with image data
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
KR101778004B1 (ko) 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
EP3658190B1 (en) 2017-07-26 2025-10-01 Oncosol Limited Liquid dosage forms of imatinib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2003231098A1 (en) * 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DE602004032310D1 (de) * 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
JP2007526886A (ja) * 2003-07-10 2007-09-20 アストラゼネカ アクチボラグ 血管新生および／または血管透過性増大に関連する疾患の処置における、プラチナ系抗腫瘍剤および任意の電離放射線と組み合わせてのキナゾリン誘導体ｚｄ６４７４の使用
EP1796672A1 (en) * 2004-09-27 2007-06-20 AstraZeneca AB Cancer combination therapy comprising azd2171 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
CA2631764A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
NO20071428L (no) 2007-04-02
MX2007003505A (es) 2007-05-10
KR20070072543A (ko) 2007-07-04
EP1804802A2 (en) 2007-07-11
WO2006035204A3 (en) 2006-10-19
AU2005288737A1 (en) 2006-04-06
US20100069398A1 (en) 2010-03-18
IL181609A0 (en) 2007-07-04
CA2578956A1 (en) 2006-04-06
BRPI0516052A (pt) 2008-08-19
WO2006035204A2 (en) 2006-04-06
US20080119479A1 (en) 2008-05-22
JP2008514577A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
AU2004255022B2 (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US20100069398A1 (en) Combination therapy
US20090325977A1 (en) Cancer combination therapy comprising azd2171 and imatinib
US20110212978A1 (en) Combination of ZD6474 and Pemetrexed
EP1965801B1 (en) Combination of azd2171 and pemetrexed
AU2005225197B2 (en) Combination therapy
CN101027059A (zh) 包含zd6474和伊马替尼的组合
WO2009118560A1 (en) Combination therapy 038
HK1123976B (en) Combination of azd2171 and pemetrexed
HK1096022B (en) Combination therapy with azd-2171
ZA200600186B (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of deseases associated with angiogenesis and/or increased vascular permeability
HK1089378B (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMBINATION COMPRISING ZD6474 ANDIMATINIB

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired